

# Takashi Suzuki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7274326/publications.pdf>

Version: 2024-02-01

174  
papers

8,075  
citations

36203

51  
h-index

64668

79  
g-index

174  
all docs

174  
docs citations

174  
times ranked

8699  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dissecting human adrenal androgen production. Trends in Endocrinology and Metabolism, 2002, 13, 234-239.	3.1	260
2	Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO Journal, 2013, 32, 1665-1680.	3.5	243
3	Estrogen-Related Receptor $\hat{\pm}$ in Human Breast Carcinoma as a Potent Prognostic Factor. Cancer Research, 2004, 64, 4670-4676.	0.4	200
4	Intratumoral Estrogens and Estrogen Receptors in Human Non-“Small Cell Lung Carcinoma. Clinical Cancer Research, 2008, 14, 4417-4426.	3.2	179
5	Accumulation of p62/SCP1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Science, 2012, 103, 760-766.	1.7	177
6	Developmental changes in steroidogenic enzymes in human postnatal adrenal cortex: immunohistochemical studies. Clinical Endocrinology, 2000, 53, 739-747.	1.2	176
7	Physiology: Immunohistochemical distribution of progesterone, androgen and oestrogen receptors in the human ovary during the menstrual cycle: relationship to expression of steroidogenic enzymes. Human Reproduction, 1994, 9, 1589-1595.	0.4	162
8	Systemic Distribution of Steroid Sulfatase and Estrogen Sulfotransferase in Human Adult and Fetal Tissues. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5760-5768.	1.8	156
9	Sex steroid-producing enzymes in human breast cancer. Endocrine-Related Cancer, 2005, 12, 701-720.	1.6	156
10	Progesterone Receptor in Non-“Small Cell Lung Cancer” A Potent Prognostic Factor and Possible Target for Endocrine Therapy. Cancer Research, 2005, 65, 6450-6458.	0.4	153
11	Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Research, 2003, 63, 2762-70.	0.4	146
12	Expression of the Steroid and Xenobiotic Receptor and Its Possible Target Gene, Organic Anion Transporting Polypeptide-A, in Human Breast Carcinoma. Cancer Research, 2006, 66, 535-542.	0.4	132
13	Aromatase Localization in Human Breast Cancer Tissues: Possible Interactions between Intratumoral Stromal and Parenchymal Cells. Cancer Research, 2007, 67, 3945-3954.	0.4	117
14	The Orphan Nuclear Receptor NGFIB Regulates Transcription of $3\hat{\beta}$ -Hydroxysteroid Dehydrogenase. Journal of Biological Chemistry, 2004, 279, 37622-37630.	1.6	113
15	Amyloid Precursor Protein Is a Primary Androgen Target Gene That Promotes Prostate Cancer Growth. Cancer Research, 2009, 69, 137-142.	0.4	105
16	Superoxide dismutase in normal cycling human ovaries: immunohistochemical localization and characterization. Fertility and Sterility, 1999, 72, 720-726.	0.5	98
17	Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10461-10466.	3.3	93
18	Estrogen Regulates Tumor Growth Through a Nonclassical Pathway that Includes the Transcription Factors ER $\hat{2}$ and KLF5. Science Signaling, 2011, 4, ra22.	1.6	92

#	ARTICLE	IF	CITATIONS
19	Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. <i>Cancer Science</i> , 2007, 98, 644-651.	1.7	91
20	New development in intracrinology of breast carcinoma. <i>Breast Cancer</i> , 2006, 13, 129-136.	1.3	86
21	In situ androgen producing enzymes in human prostate cancer. <i>Endocrine-Related Cancer</i> , 2005, 12, 101-107.	1.6	84
22	Human liver-specific organic anion transporter is a potent prognostic factor for human breast carcinoma. <i>Cancer Science</i> , 2007, 98, 1570-1576.	1.7	83
23	TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer. <i>Oncogene</i> , 2018, 37, 2165-2180.	2.6	83
24	Steroid Sulfatase and Estrogen Sulfotransferase in Human Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 5850-5856.	3.2	81
25	<i>In situ</i> estrogen production and its regulation in human breast carcinoma: From endocrinology to intracrinology. <i>Pathology International</i> , 2009, 59, 777-789.	0.6	80
26	Colocalization of 11 $\beta$ -Hydroxysteroid Dehydrogenase Type II and Mineralocorticoid Receptor in Human Epithelia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3859-3863.	1.8	75
27	Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer. <i>Cancer Research</i> , 2005, 65, 657-63.	0.4	75
28	Adrenal changes associated with adrenarche. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2009, 10, 19-26.	2.6	74
29	Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues. <i>International Journal of Cancer</i> , 2013, 132, 1368-1382.	2.3	74
30	Association of USP10 with G3BP2 Inhibits p53 Signaling and Contributes to Poor Outcome in Prostate Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 846-856.	1.5	74
31	Intracrinology of estrogens and androgens in breast carcinoma. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2008, 108, 181-185.	1.2	73
32	Aromatase inhibitor treatment of breast cancer cells increases the expression of <i>let-7f</i> , a microRNA targeting <i>CYP19A1</i> . <i>Journal of Pathology</i> , 2012, 227, 357-366.	2.1	73
33	5 $\alpha$ -Reductase type 1 and aromatase in breast carcinoma as regulators of <i>in situ</i> androgen production. <i>International Journal of Cancer</i> , 2007, 120, 285-291.	2.3	71
34	Development of the human adrenal zona reticularis: morphometric and immunohistochemical studies from birth to adolescence. <i>Journal of Endocrinology</i> , 2009, 203, 241-252.	1.2	71
35	Androgenic pathway in triple negative invasive ductal tumors: Its correlation with tumor cell proliferation. <i>Cancer Science</i> , 2013, 104, 639-646.	1.7	71
36	Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma <i>in situ</i> of human breast. <i>Endocrine-Related Cancer</i> , 2008, 15, 113-124.	1.6	70

#	ARTICLE	IF	CITATIONS
37	RNA-binding protein NONO promotes breast cancer proliferation by post-transcriptional regulation of SKP2 and E2F8. <i>Cancer Science</i> , 2020, 111, 148-159.	1.7	67
38	Estrogen-Responsive Finger Protein as a New Potential Biomarker for Breast Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 6148-6154.	3.2	65
39	Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003, 86, 449-454.	1.2	64
40	Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. <i>Endocrine-Related Cancer</i> , 2010, 17, 415-430.	1.6	64
41	5 $\alpha$ -Reductases in Human Breast Carcinoma: Possible Modulator of In Situ Androgenic Actions. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2250-2257.	1.8	61
42	Highly concordant coexpression of aromatase and estrogen receptor $\beta$ in non-small cell lung cancer. <i>Human Pathology</i> , 2010, 41, 190-198.	1.1	61
43	Sex steroid receptors in rheumatoid arthritis. <i>Clinical Science</i> , 2004, 106, 293-300.	1.8	59
44	Nucleobindin 2 in human breast carcinoma as a potent prognostic factor. <i>Cancer Science</i> , 2012, 103, 136-143.	1.7	59
45	Hexokinase II in breast carcinoma: A potent prognostic factor associated with hypoxia-inducible factor $1\alpha$ and K $\alpha$ . <i>Cancer Science</i> , 2013, 104, 1380-1388.	1.7	59
46	Urocortin and Corticotropin-Releasing Factor Receptor Expression in Normal Cycling Human Ovaries. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1362-1369.	1.8	56
47	Steroid Sulfotransferase 2A1 Gene Transcription Is Regulated by Steroidogenic Factor 1 and GATA-6 in the Human Adrenal. <i>Molecular Endocrinology</i> , 2005, 19, 184-197.	3.7	56
48	Steroid Sulfatase and Estrogen Sulfotransferase in Colon Carcinoma: Regulators of Intratumoral Estrogen Concentrations and Potent Prognostic Factors. <i>Cancer Research</i> , 2009, 69, 914-922.	0.4	56
49	Steroid sulfatase and estrogen sulfotransferase in human prostate cancer. <i>Prostate</i> , 2006, 66, 1005-1012.	1.2	55
50	NRF2 immunolocalization in human breast cancer patients as a prognostic factor. <i>Endocrine-Related Cancer</i> , 2014, 21, 241-252.	1.6	55
51	Cancer-associated fibroblasts secrete Wnt2 to promote cancer progression in colorectal cancer. <i>Cancer Medicine</i> , 2019, 8, 6370-6382.	1.3	55
52	Runt-related transcription factor 2 in human colon carcinoma: A potent prognostic factor associated with estrogen receptor. <i>International Journal of Cancer</i> , 2012, 131, 2284-2293.	2.3	53
53	Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast carcinoma: Possible regulator of in situ steroidogenesis. <i>Cancer Letters</i> , 2006, 244, 24-33.	3.2	52
54	17 $\beta$ -Hydroxysteroid Dehydrogenase Types 1 and 2 in Human Placenta: An Immunohistochemical Study with Correlation to Placental Development. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 3710-3715.	1.8	51

#	ARTICLE	IF	CITATIONS
55	Amyloid precursor protein in human breast cancer: An androgen-induced gene associated with cell proliferation. <i>Cancer Science</i> , 2013, 104, 1532-1538.	1.7	51
56	Effects of steroid hormones on vascular functions. <i>Microscopy Research and Technique</i> , 2003, 60, 76-84.	1.2	50
57	17 $\beta$ -Hydroxysteroid dehydrogenases in human endometrium and its disorders. <i>Molecular and Cellular Endocrinology</i> , 2006, 248, 136-140.	1.6	50
58	PSF Promotes ER-Positive Breast Cancer Progression via Posttranscriptional Regulation of <i>ESR1</i> and <i>SCFD2</i> . <i>Cancer Research</i> , 2020, 80, 2230-2242.	0.4	50
59	Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-mediated invasion and a potent prognostic factor. <i>Endocrine-Related Cancer</i> , 2007, 14, 279-292.	1.6	49
60	Intratumoral Localization of Aromatase and Interaction between Stromal and Parenchymal Cells in the Non-Small Cell Lung Carcinoma Microenvironment. <i>Cancer Research</i> , 2010, 70, 6659-6669.	0.4	49
61	11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 in Human Lung: Possible Regulator of Mineralocorticoid Action. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 4022-4025.	1.8	48
62	Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 144, 513-522.	1.2	48
63	Transcriptional Regulation of Dehydroepiandrosterone Sulfotransferase (SULT2A1) by Estrogen-Related Receptor $\alpha$ . <i>Endocrinology</i> , 2005, 146, 3605-3613.	1.4	47
64	The Analyses of 17 $\beta$ -Hydroxysteroid Dehydrogenase Isozymes in Human Endometrial Hyperplasia and Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3436-3443.	1.8	46
65	Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: A possible androgenic bone protective effects induced by exemestane. <i>Bone</i> , 2007, 40, 876-887.	1.4	46
66	<i>ESR1</i> -Stabilizing Long Noncoding RNA <i>TMPO-AS1</i> Promotes Hormone-Refractory Breast Cancer Progression. <i>Molecular and Cellular Biology</i> , 2019, 39, .	1.1	46
67	TACC2 Is an Androgen-Responsive Cell Cycle Regulator Promoting Androgen-Mediated and Castration-Resistant Growth of Prostate Cancer. <i>Molecular Endocrinology</i> , 2012, 26, 748-761.	3.7	45
68	Sex steroid receptors expression and hormone-induced cell proliferation in human osteosarcoma. <i>Cancer Science</i> , 2008, 99, 518-523.	1.7	44
69	Increased estrogen sulfatase (STS) and 17 $\beta$ -hydroxysteroid dehydrogenase type 1 (17 $\beta$ -HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 639-648.	1.1	44
70	Urocortin 1, Urocortin 3/Stresscopin, and Corticotropin-Releasing Factor Receptors in Human Adrenal and Its Disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4671-4678.	1.8	43
71	Nur-Related Factor 1 and Nerve Growth Factor-Induced Clone B in Human Adrenal Cortex and Its Disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4113-4118.	1.8	42
72	Steroid Sulfatase and Estrogen Sulfotransferase in the Atherosclerotic Human Aorta. <i>American Journal of Pathology</i> , 2003, 163, 1329-1339.	1.9	40

#	ARTICLE	IF	CITATIONS
73	Expression of Urocortin and Corticotropin-Releasing Factor Receptor Subtypes in the Human Heart. , O, .		40
74	Kr $\beta$ 4ppl-like factor 5 in human breast carcinoma: a potent prognostic factor induced by androgens. Endocrine-Related Cancer, 2012, 19, 741-750.	1.6	39
75	<sc>OLFM</sc>4, <sc>LY</sc>6D and S100A7 as potent markers for distant metastasis in estrogen receptor $\epsilon$ positive breast carcinoma. Cancer Science, 2018, 109, 3350-3359.	1.7	39
76	Immunohistochemical distribution of 11 $\beta$ -hydroxysteroid dehydrogenase in human eye. Molecular and Cellular Endocrinology, 2001, 173, 121-125.	1.6	38
77	17 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 and 2 Expression in the Human Fetus1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 410-416.	1.8	37
78	Nudix $\epsilon$ type motif 2 in human breast carcinoma: A potent prognostic factor associated with cell proliferation. International Journal of Cancer, 2011, 128, 1770-1782.	2.3	37
79	Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment. Breast Cancer Research, 2017, 19, 70.	2.2	37
80	Progesterone receptor isoforms as a prognostic marker in human endometrial carcinoma. Cancer Science, 2006, 97, 1308-1314.	1.7	36
81	17 $\beta$ -Hydroxysteroid Dehydrogenase Type 12 in Human Breast Carcinoma: A Prognostic Factor via Potential Regulation of Fatty Acid Synthesis. Cancer Research, 2009, 69, 1392-1399.	0.4	36
82	Chicken ovalbumin upstream promoter transcription factor II in human breast carcinoma: Possible regulator of lymphangiogenesis via vascular endothelial growth factor $\epsilon$ expression. Cancer Science, 2009, 100, 639-645.	1.7	36
83	Androgens in human breast carcinoma. Medical Molecular Morphology, 2010, 43, 75-81.	0.4	36
84	Steroid sulfatase and estrogen sulfotransferase in human carcinomas. Molecular and Cellular Endocrinology, 2011, 340, 148-153.	1.6	36
85	Messenger Ribonucleic Acid in Situ Hybridization Analysis of Estrogen Receptors $\alpha$ and $\beta$ in Human Breast Carcinoma1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 781-785.	1.8	34
86	Intracrine mechanism of estrogen synthesis in breast cancer. Biomedicine and Pharmacotherapy, 2003, 57, 460-462.	2.5	34
87	In situ production of sex steroids in human breast carcinoma. Medical Molecular Morphology, 2007, 40, 121-127.	0.4	34
88	BUB1 Immunolocalization in Breast Carcinoma: Its Nuclear Localization as a Potent Prognostic Factor of the Patients. Hormones and Cancer, 2013, 4, 92-102.	4.9	34
89	Hexokinase 2 in colorectal cancer: a potent prognostic factor associated with glycolysis, proliferation and migration. Histology and Histopathology, 2017, 32, 351-360.	0.5	34
90	11 $\beta$ -Hydroxysteroid Dehydrogenase Type II and Mineralocorticoid Receptor in Human Placenta1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1306-1309.	1.8	32

#	ARTICLE	IF	CITATIONS
91	Aromatase in Human Breast Carcinoma as a Key Regulator of Intratumoral Sex Steroid Concentrations. <i>Endocrine Journal</i> , 2008, 55, 455-463.	0.7	32
92	An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma. <i>Journal of Translational Medicine</i> , 2012, 10, S2.	1.8	32
93	The role of 5 $\alpha$ -reductase type 1 associated with intratumoral dihydrotestosterone concentrations in human endometrial carcinoma. <i>Molecular and Cellular Endocrinology</i> , 2015, 401, 56-64.	1.6	32
94	11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 and Mineralocorticoid Receptor in Human Fetal Development. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1453-1458.	1.8	31
95	Localization of Steroidogenesis and Steroid Receptors in Human Corpus Luteum. <i>Seminars in Reproductive Medicine</i> , 1997, 15, 345-352.	0.5	30
96	ALDH1A1 in patient-derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression. <i>International Journal of Cancer</i> , 2020, 146, 1099-1113.	2.3	30
97	Retinoid Receptors in Human Breast Carcinoma: Possible Modulators of in Situ Estrogen Metabolism. <i>Breast Cancer Research and Treatment</i> , 2001, 65, 31-40.	1.1	29
98	TRIM44 promotes cell proliferation and migration by inhibiting FRK in renal cell carcinoma. <i>Cancer Science</i> , 2020, 111, 881-890.	1.7	29
99	Intratumoral estrogen production in breast carcinoma: significance of aromatase. <i>Breast Cancer</i> , 2008, 15, 270-277.	1.3	28
100	17 $\beta$ -Hydroxysteroid Dehydrogenases in Human Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 2009, 1155, 25-32.	1.8	28
101	New Developments in Intracrinology of Human Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 2009, 1155, 76-79.	1.8	28
102	Controversies of aromatase localization in human breast cancer—Stromal versus parenchymal cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007, 106, 97-101.	1.2	27
103	L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism. <i>Scientific Reports</i> , 2021, 11, 589.	1.6	27
104	Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: Estrogen receptor dependent or independent pathways of raloxifene. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009, 113, 281-289.	1.2	26
105	Expression of (pro)renin receptor in breast cancers and its effect on cancer cell proliferation. <i>Biomedical Research</i> , 2014, 35, 117-126.	0.3	25
106	Increased 5 $\alpha$ -Reductase Type 2 Expression in Human Breast Carcinoma following Aromatase Inhibitor Therapy: The Correlation with Decreased Tumor Cell Proliferation. <i>Hormones and Cancer</i> , 2011, 2, 73-81.	4.9	24
107	In situ androgen and estrogen biosynthesis in endometrial cancer: focus on androgen actions and intratumoral production. <i>Endocrine-Related Cancer</i> , 2016, 23, R323-R335.	1.6	24
108	TRIM47 activates NF- $\kappa$ B signaling via PKC- $\mu$ /PKD3 stabilization and contributes to endocrine therapy resistance in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	24

#	ARTICLE	IF	CITATIONS
109	Immunolocalization of estrogen-producing and metabolizing enzymes in benign breast disease: Comparison with normal breast and breast carcinoma. <i>Cancer Science</i> , 2010, 101, 2286-2292.	1.7	23
110	Associations of obesity and physical activity with serum and intratumoral sex steroid hormone levels among postmenopausal women with breast cancer: analysis of paired serum and tumor tissue samples. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 115-125.	1.1	23
111	Wnt5a in cancer-associated fibroblasts promotes colorectal cancer progression. <i>Biochemical and Biophysical Research Communications</i> , 2021, 568, 37-42.	1.0	23
112	In situ detection of estrogen receptor dimers in breast carcinoma cells in archival materials using proximity ligation assay (PLA). <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 165, 159-169.	1.2	22
113	In situ production of estrogens in human breast carcinoma. <i>Breast Cancer</i> , 2002, 9, 296-302.	1.3	21
114	Role of Local 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Expression in Determining the Phenotype of Adrenal Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 864-870.	1.8	21
115	The AP-1 family member FOS blocks transcriptional activity of the nuclear receptor steroidogenic factor 1. <i>Journal of Cell Science</i> , 2010, 123, 3956-3965.	1.2	21
116	Intratumoral localization and activity of 17 $\beta$ -hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factor. <i>Journal of Translational Medicine</i> , 2013, 11, 167.	1.8	21
117	p62/sequestosome 1 in human colorectal carcinoma as a potent prognostic predictor associated with cell proliferation. <i>Cancer Medicine</i> , 2017, 6, 1264-1274.	1.3	21
118	COBLL1 modulates cell morphology and facilitates androgen receptor genomic binding in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 4975-4980.	3.3	21
119	Abnormal expression of miR-1 in breast carcinoma as a potent prognostic factor. <i>Cancer Science</i> , 2015, 106, 1642-1650.	1.7	20
120	11 $\beta$ -Prostaglandin F $_{2\alpha}$ , a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2015, 413, 236-247.	1.6	20
121	Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer. <i>Nature Communications</i> , 2021, 12, 3766.	5.8	20
122	Benign cortisol-secreting adrenocortical adenomas produce small amounts of androgens. <i>Clinical Endocrinology</i> , 2007, 66, 778-788.	1.2	19
123	Ovarian epithelial carcinoma with estrogen-producing stroma. <i>Pathology International</i> , 2007, 57, 285-290.	0.6	19
124	Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: Comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009, 114, 68-71.	1.2	19
125	Steroid and xenobiotic receptor in human esophageal squamous cell carcinoma: A potent prognostic factor. <i>Cancer Science</i> , 2010, 101, 543-549.	1.7	19
126	TACC2 (transforming acidic coiled-coil protein 2) in breast carcinoma as a potent prognostic predictor associated with cell proliferation. <i>Cancer Medicine</i> , 2016, 5, 1973-1982.	1.3	19



#	ARTICLE	IF	CITATIONS
127	Roles of Aryl Hydrocarbon Receptor in Aromatase-Dependent Cell Proliferation in Human Osteoblasts. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2159.	1.8	19
128	Increased expression of 11beta-hydroxysteroid dehydrogenase type 2 in the lungs of patients with acute respiratory distress syndrome. <i>Pathology International</i> , 2003, 53, 751-756.	0.6	18
129	Relaxin 2/RXFP1 Signaling Induces Cell Invasion via the $\beta$ -Catenin Pathway in Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2438.	1.8	18
130	Systemic distribution of estrogen-responsive finger protein (Efp) in human tissues. <i>Molecular and Cellular Endocrinology</i> , 2004, 218, 147-153.	1.6	17
131	Steroid and xenobiotic receptor-mediated effects of bisphenol A on human osteoblasts. <i>Life Sciences</i> , 2016, 155, 29-35.	2.0	17
132	Inflammatory Mediators Down-Regulate 11.BETA.-Hydroxysteroid Dehydrogenase Type 2 in a Human Lung Epithelial Cell Line BEAS-2B and the Rat Lung. <i>Tohoku Journal of Experimental Medicine</i> , 2005, 207, 293-301.	0.5	16
133	GATA4 immunolocalization in breast carcinoma as a potent prognostic predictor. <i>Cancer Science</i> , 2014, 105, 600-607.	1.7	16
134	Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 399-407.	1.1	16
135	ARHGAP15 in Human Breast Carcinoma: A Potent Tumor Suppressor Regulated by Androgens. <i>International Journal of Molecular Sciences</i> , 2018, 19, 804.	1.8	16
136	Stromal CCL5 Promotes Breast Cancer Progression by Interacting with CCR3 in Tumor Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1918.	1.8	16
137	<sc>CITED</sc>2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance. <i>Cancer Science</i> , 2016, 107, 1898-1908.	1.7	15
138	Hormonal Regulation of Patient-Derived Endometrial Cancer Stem-like Cells Generated by Three-Dimensional Culture. <i>Endocrinology</i> , 2019, 160, 1895-1906.	1.4	15
139	Cytochrome c1 in ductal carcinoma <i>in situ</i> of breast associated with proliferation and comedo necrosis. <i>Cancer Science</i> , 2017, 108, 1510-1519.	1.7	14
140	Targeting Amino Acid Metabolic Reprogramming via L-Type Amino Acid Transporter 1 (LAT1) for Endocrine-Resistant Breast Cancer. <i>Cancers</i> , 2021, 13, 4375.	1.7	14
141	Intratumoral Estrogen Concentration and Expression of Estrogen-Induced Genes in Male Breast Carcinoma: Comparison with Female Breast Carcinoma. <i>Hormones and Cancer</i> , 2013, 4, 1-11.	4.9	13
142	Immunolocalization of Corticotropin-Releasing Hormone (CRH) and Its Receptors (CRHR1 and CRHR2) in Human Endometrial Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1549-1557.	1.2	13
143	17 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Expression Is Induced by Androgen Signaling in Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1139.	1.8	13
144	Rac1 activation in human breast carcinoma as a prognostic factor associated with therapeutic resistance. <i>Breast Cancer</i> , 2020, 27, 919-928.	1.3	13

#	ARTICLE	IF	CITATIONS
145	Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma. <i>Oncogene</i> , 2021, 40, 3899-3913.	2.6	13
146	Estrogen Inhibits Cell Proliferation through In situ Production in Human Thymoma. <i>Clinical Cancer Research</i> , 2005, 11, 6495-6504.	3.2	12
147	Androgen and androgen-metabolizing enzymes in metastasized lymph nodes of breast cancer. <i>Human Pathology</i> , 2013, 44, 2338-2345.	1.1	12
148	Tissue concentrations of estrogens and aromatase immunolocalization in interstitial pneumonia of human lung. <i>Molecular and Cellular Endocrinology</i> , 2014, 392, 136-143.	1.6	12
149	Progesterone Metabolism in Human Leukemic Monoblast U937 Cells.. <i>Endocrine Journal</i> , 2002, 49, 539-546.	0.7	11
150	Oestrogen-induced genes in ductal carcinoma in situ: their comparison with invasive ductal carcinoma. <i>Endocrine-Related Cancer</i> , 2012, 19, 485-496.	1.6	11
151	Human 3 $\beta$ -hydroxysteroid dehydrogenase type 1 in human breast cancer: clinical significance and prognostic associations. <i>Cancer Medicine</i> , 2016, 5, 1405-1415.	1.3	11
152	Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapyâ€‘Refractory Cancer Growth. <i>Cancer Research</i> , 2021, 81, 3495-3508.	0.4	11
153	Analysis of gene expression induced by diethylstilbestrol (DES) in human primitive Mullerian duct cells using microarray. <i>Cancer Letters</i> , 2005, 220, 197-210.	3.2	10
154	Aromatase and in situ estrogen production in DCIS (ductal carcinoma in situ) of human breast. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 118, 242-245.	1.2	10
155	The interplay of endocrine therapy, steroid pathways and therapeutic resistance: Importance of androgen in breast carcinoma. <i>Molecular and Cellular Endocrinology</i> , 2018, 466, 31-37.	1.6	10
156	A metabolic profile of routine needle biopsies identified tumor type specific metabolic signatures for breast cancer stratification: a pilot study. <i>Metabolomics</i> , 2019, 15, 147.	1.4	10
157	Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases. <i>Breast Cancer</i> , 2021, 28, 915-926.	1.3	10
158	Analysis for Localization of Steroid Sulfatase in Human Tissues. <i>Methods in Enzymology</i> , 2005, 400, 303-316.	0.4	9
159	Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast. <i>Cancer Science</i> , 2014, 105, 1503-1509.	1.7	9
160	Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 45-55.	1.1	8
161	Forkhead Box 11 in Breast Carcinoma as a Potent Prognostic Factor. <i>Acta Histochemica Et Cytochemica</i> , 2021, 54, 123-130.	0.8	8
162	Ductal carcinoma in situ and related lesions of the breast: Recent advances in pathology practice. <i>Breast Cancer</i> , 2004, 11, 325-333.	1.3	7

#	ARTICLE	IF	CITATIONS
163	Cyclin-dependent kinase-specific activity predicts the prognosis of stage I and stage II non-small cell lung cancer. <i>BMC Cancer</i> , 2014, 14, 755.	1.1	7
164	Co-expression of nuclear heterogeneous nuclear ribonucleic protein K and estrogen receptor $\beta$ in endometrial cancer. <i>Pathology Research and Practice</i> , 2022, 231, 153795.	1.0	7
165	Retinoic Acid Receptor $\beta$ : A Potential Therapeutic Target in Retinoic Acid Treatment of Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 643-650.	1.2	6
166	PSPC1 is a potential prognostic marker for hormone-dependent breast cancer patients and modulates RNA processing of ESR1 and SCFD2. <i>Scientific Reports</i> , 2022, 12, .	1.6	6
167	Retinoid receptors in human esophageal squamous cell carcinoma: Retinoid X receptor as a potent prognostic factor. <i>Pathology International</i> , 2011, 61, 401-408.	0.6	5
168	Immunohistochemical analysis of aromatase in metastatic lymph nodes of breast cancer. <i>Pathology International</i> , 2013, 63, 20-28.	0.6	5
169	Identification and Functional Characterization of a Novel Androgen Receptor Coregulator, EAP1. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab150.	0.1	4
170	Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma. <i>Histology and Histopathology</i> , 2019, 34, 1365-1375.	0.5	4
171	Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor. <i>Acta Histochemica Et Cytochemica</i> , 2022, 55, 25-35.	0.8	4
172	D-2-hydroxyglutarate dehydrogenase in breast carcinoma as a potent prognostic marker associated with proliferation. <i>Histology and Histopathology</i> , 2021, , 18362.	0.5	3
173	Clinicopathological and Preclinical Patient-Derived Model Studies Define High Expression of NRN1 as a Diagnostic and Therapeutic Target for Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 758503.	1.3	1
174	New development in intracrinology of breast carcinoma: therapeutic horizons after aromatase inhibitors. <i>Expert Review of Endocrinology and Metabolism</i> , 2007, 2, 367-374.	1.2	0